Lupin receives FDA approval for generic Triamcinolone Acetonide Ointment USP, 0.1 per cent
Pharma major Lupin announced that it has received approval for its Triamcinolone Acetonide Ointment USP, 0.1 per cent from the US Food and Drug Administration (FDA) to market a generic version of Mylan Pharmaceuticals, (Mylan) Triamcinolone Acetonide Ointment, 0.1 per cent.
Lupin’s Triamcinolone Acetonide Ointment USP, 0.1 per cent is the generic version of Mylan’s Triamcinolone Acetonide Ointment, 0.1 per cent. It is indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses.
Triamcinolone Acetonide Ointment USP, 0.1 per cent had annual sales of approximately USD 25.7 million in the US